# Extension Safety and Immunogenicity Study of GPNV-001

> **NCT05982314** · PHASE1,PHASE2 · COMPLETED · sponsor: **GPN Vaccines** · enrollment: 60 (actual)

## Conditions studied

- Pneumococcal Infections

## Interventions

- **BIOLOGICAL:** Gamma-PN3
- **BIOLOGICAL:** Pneumovax-23
- **BIOLOGICAL:** Prevenar-13
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT05982314
- **Lead sponsor:** GPN Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-17
- **Primary completion:** 2024-08-30
- **Final completion:** 2024-08-30
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2024-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05982314

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05982314, "Extension Safety and Immunogenicity Study of GPNV-001". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05982314. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*